Physician profile
Crystal Boyer
NPI 1780230623
$2,461.69
in general payments reported to CMS, 2019-2025
29 companies · $2,130 in 2025
The $2,130 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.67 · 2022: $79.69 · 2023: $56.27 · 2024: $163 · 2025: $2,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $273.42 | 2025 | |
| Janssen Biotech, INC. | $229.95 | 2025 | Tremfya |
| Novo Nordisk INC | $180.29 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $146.45 | 2025 | Zenpep, Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.25 | 2025 | Xifaxan |
| Genzyme Corporation | $141.72 | 2025 | |
| Madrigal Pharmaceuticals | $139.24 | 2025 | Rezdiffra |
| Pfizer INC. | $137.78 | 2025 | |
| Ardelyx, INC. | $129.65 | 2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $119.41 | 2025 | Iqirvo |
| Lilly USA, LLC | $107.44 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $102.85 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $97.71 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $92.93 | 2025 | Entyvio, Gattex, Eohilia |
| Kci USA, INC. | $52.28 | 2021-2023 | Activ.A.C., Prevena, V.A.C. Veraflo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $49.49 | 2021-2024 | Xarelto |
| Medtronic, INC. | $43.75 | 2022-2024 | Azure Xt Dr Mri Surescan |
| Intercept Pharmaceuticals, INC. | $36.48 | 2025 | |
| Daiichi Sankyo INC. | $27.07 | 2025 | Injectafer |
| Celltrion USA INC. | $26.50 | 2025 | Vegzelma |
| Abbott Laboratories | $24.74 | 2024 | Esprit |
| Cashflow Solutions, LLC | $23.07 | 2022-2024 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Solventum Corporation | $22.35 | 2024 | Promogran Prisma, Activ.A.C. |
| Heron Therapeutics, INC. | $21.92 | 2022 | |
| Cardiovascular Systems INC. | $21.58 | 2023 | Diamondback Peripheral |
| Ethicon US, LLC | $19.93 | 2024 | Echelon; Endopath |
| Convatec INC. | $17.28 | 2024 | |
| Organon LLC | $17.03 | 2025 | Hadlima, Renflexis |
| Orphalan INC | $15.13 | 2025 | Cuvrior |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Boyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.